• Annexin V-FITC/PI Apoptosis Assay Kit: Protocol and Troubles

  2026-08-06

  The Annexin V-FITC/PI Apoptosis Assay Kit enables researchers to distinguish viable, early apoptotic, and late apoptotic/necrotic cells using a rapid, fluorescence-based staining protocol. It is suited for flow cytometry and fluorescence microscopy workflows requiring clear separation of cell death stages. This kit should not be used for diagnostic or clinical applications, and performance outside recommended storage or staining conditions is not validated.

• AO/PI Double Staining Kit: Practical Guide to Cell Viability

  2026-08-05

  The AO/PI Double Staining Kit enables rapid, dual-fluorescent discrimination of viable, apoptotic, and necrotic cells in cell biology assays. Designed for routine use in viability, apoptosis, and necrosis detection, it is best suited for fluorescence microscopy or flow cytometry workflows where clear identification of cell health states is essential. The kit should not be used in non-fluorescence-based assays or for applications requiring mechanistic quantification beyond membrane integrity and nuclear morphology.

• Meropenem: Experimental Workflows in Resistance Modeling

  2026-08-05

  Meropenem stands out as a robust β-lactam antibiotic carbapenem for high-fidelity modeling of Gram-negative and Gram-positive bacterial resistance. This guide delivers actionable protocol enhancements, troubleshooting insights, and comparative context for scientists driving translational research.

• MK-2206 dihydrochloride: Targeted Akt Inhibition in Cancer a

  2026-08-04

  MK-2206 dihydrochloride stands out as a potent, selective allosteric Akt inhibitor for dissecting PI3K/Akt/mTOR signaling in cancer, apoptosis, and metabolic disease models. This guide delivers advanced workflows, troubleshooting strategies, and highlights how recent glycolytic control discoveries reshape experiment design.

• FTSJ3 Loss Drives R-Loop DNA Damage and Chemosensitivity in

  2026-08-04

  This study identifies FTSJ3 as a critical regulator of R-loop homeostasis and genomic integrity in lung cancer cells. The findings reveal that FTSJ3 depletion increases R-loop-associated DNA damage and sensitizes tumor cells to cisplatin, highlighting FTSJ3 as a potential biomarker for chemotherapy responsiveness.

• Zoledronic Acid: Advanced Workflows for Cancer and Bone Dise

  2026-08-03

  Zoledronic Acid, a potent nitrogen-containing bisphosphonate from APExBIO, enables precise modeling of cancer cell apoptosis and osteolytic bone disease in preclinical studies. This guide details actionable protocol enhancements, troubleshooting strategies, and the translational impact of recent mechanistic insights, driving higher reproducibility and data quality for oncology and bone research.

• Nicotinamide Adenine Dinucleotide (NAD+): Workflow Advances

  2026-08-03

  Nicotinamide Adenine Dinucleotide (NAD+) is transforming metabolic and autophagy research, offering precise control and readout in stress signaling assays. APExBIO's NAD+ enables robust, reproducible workflows and unlocks new troubleshooting strategies for energy stress studies.

• Redefining In Vitro Drug Response Metrics in Cancer Research

  2026-08-02

  Schwartz's dissertation establishes how relative viability and fractional viability capture distinct facets of anti-cancer drug effects, challenging the longstanding practice of treating them as interchangeable. This work provides a refined methodological framework for evaluating cell cycle arrest and apoptosis, informing the rational use of mitotic inhibitors such as SB743921 in preclinical cancer models.

• Hesperadin: Precision Aurora B Kinase Inhibition in Mitosis

  2026-08-01

  Hesperadin empowers researchers to dissect mitotic progression with high specificity by targeting Aurora B kinase, making it ideal for advanced cell cycle and cancer research. This guide bridges mechanistic insight with reproducible workflows, protocol enhancements, and troubleshooting strategies, drawing on the latest literature and validated protocols.

• LY364947: Optimizing TGF-β Type I Receptor Kinase Inhibition

  2026-07-31

  LY364947, a selective TGF-β type I receptor kinase inhibitor from APExBIO, enables precise EMT modulation and advanced anti-fibrotic research. Discover workflow enhancements, troubleshooting strategies, and translational insights for maximizing its impact in cellular and in vivo studies.

• Scenario-Driven Solutions with HyperScript™ Reverse Transcri

  2026-07-31

  This article addresses common laboratory hurdles in cDNA synthesis workflows—especially for RNA templates with low abundance or complex secondary structures—and demonstrates, through scenario-driven Q&A, how HyperScript™ Reverse Transcriptase (SKU K1071) offers robust, reproducible solutions. By integrating peer-reviewed findings and practical protocol guidance, biomedical researchers can optimize qPCR and molecular assays with heightened reliability.

• Novel Tetrahydroisoquinoline P-gp Inhibitors Reverse MDR in

  2026-07-30

  This study reports the rational design and synthesis of 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline derivatives as potent P-glycoprotein inhibitors, demonstrating robust reversal of multidrug resistance in Eca109/VCR esophageal cancer cells. The findings suggest new directions for overcoming chemoresistance with optimized molecular scaffolds.

• Regulated Platelet Extravasation via CXCL12/CXCR4 Drives Tum

  2026-07-30

  This study defines the molecular mechanisms by which platelets exit the vasculature and infiltrate tumors, identifying stromal CXCL12/CXCR4 signaling as a critical control point. Disruption of this axis, along with key cytoskeletal and adhesion factors, reduces platelet infiltration and tumor growth, highlighting new therapeutic targets in the tumor microenvironment.

• Tigecycline in Translational Research: From Mechanism to Str

  2026-07-29

  This article provides translational researchers with an integrated perspective on Tigecycline—a pioneering glycylcycline antibiotic—highlighting its unique mechanism, experimental validation in multidrug-resistant models, and strategic value in the evolving landscape of antimicrobial resistance. By connecting mechanistic insights to real-world challenges such as carbapenem-resistant Enterobacter cloacae, the discussion advances beyond conventional product summaries and offers actionable guidance for research design and clinical translation.

• Nocodazole: Microtubule Polymerization Inhibitor in Modern R

  2026-07-29

  Nocodazole offers unmatched control for dissecting microtubule dynamics, cell cycle checkpoints, and anticancer mechanisms. This guide translates the latest chromatin remodeling discoveries into optimized, data-driven workflows for researchers leveraging APExBIO’s Nocodazole.

8743 records 10/583 page Previous Next First page 上5页 678910 下5页 Last page